#biotechsky
LightNews LightNews
markfortner.bsky.social
A human subject has been injected with an AI-designed virus aiming to kill antibiotic resistant bacteria... | #AI #DrugDiscovery #biotechsky
A human subject has been injected with an AI-designed virus aiming to kill antibiotic-resistant bacteria, so let's see how that turns out
Welcome to clinical AI in 2026
www.techradar.com
November 1, 2026 at 3:23 PM
markfortner.bsky.social
New Pancreatic #Cancer Vaccine Sparked Immune Response in 99% of Patients | #PancreaticCancer #IO #Vaccine #biotechsky #biotech
New Pancreatic Cancer Vaccine Sparked Immune Responses in 99% of Patients
Pancreatic cancer is incredibly difficult to shake.
www.sciencealert.com
October 30, 2026 at 2:16 PM
markfortner.bsky.social
AstraZeneca launches $1.5B savings plan to fuel pipeline growth, says workforce won't shrink | #biotechsky #pharma
AstraZeneca launches $1.5B savings plan to fuel pipeline growth, says workforce won't shrink
Facing looming patent cliffs, AstraZeneca has launched a restructuring initiative aimed at generating $1.5 billion in annual savings by 2029. | Facing looming patent cliffs, AstraZeneca has launched a...
www.fiercepharma.com
October 31, 2026 at 1:58 PM
markfortner.bsky.social
AstraZeneca readies new portfolio of targeted cancer therapies | #pharma #biotechsky #cancer
AstraZeneca Readies New Portfolio of Targeted Cancer Therapies
AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to cement its position in one of the fastest-growing corners of the oncology marke...
www.wsj.com
October 27, 2026 at 6:47 PM
markfortner.bsky.social
The biotech leader who erased team lanes | #biotech #biotechsky #ProjectManagement
The Biotech Leader Who Erased Team Lanes
The Biotech Leader Who Erased Team Lanes
www.wsj.com
October 27, 2026 at 2:44 PM
markfortner.bsky.social
'The patient needs is enormous': Syntax programs stem cells into pancreatic beta cells in 4 days | #biotechsky #biotech
‘The patient need is enormous’: Syntax programs stem cells into pancreatic beta cells in 4 days
Chicago-based Syntax Bio believes it has cracked the code for turning stem cells into pancreatic beta cells in as little as four days. | Chicago-based Syntax Bio believes it has cracked the code for t...
www.fiercebiotech.com
October 29, 2026 at 2:56 PM
markfortner.bsky.social
San Diego #biotech plays off nearly all of its staff after drug trial failure into patient deaths | #biotechsky
San Diego biotech lays off nearly all its staff after drug trial failure and 2 patient deaths
San Diego biotech is abandoning its lead immunotherapy treatment for rheumatoid arthritis roughly five months after raising about $300 million from investors.
www.sandiegouniontribune.com
October 28, 2026 at 2:49 PM
markfortner.bsky.social
Incyte pancreatic cancer medicine induced lasting tumor responses | #biotech #biotechsky #cancer #PancreaticCancer
Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
A targeted drug from Incyte, when used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancer.
www.statnews.com
October 27, 2026 at 6:42 PM
markfortner.bsky.social
ESMO: Bristol Myers CMO touts ‘5 out of 5’ positive phase 3 trials for bispecific ADC iza-bren www.fiercepharma.com/pharma/brist...

#biotech #pharma #biotechsky
ESMO: Bristol Myers CMO touts ‘5 out of 5’ positive phase 3 trials for bispecific ADC iza-bren
Buoyed by a clean sweep of five positive phase 3 readouts in China, Bristol Myers Squibb’s Chief Medical Officer, Cristian Massacesi, M.D., is voicing growing confidence in the company's first-in-c | ...
www.fiercepharma.com
October 26, 2026 at 3:45 PM
markfortner.bsky.social
ESMO: J&J exec says RIPTAC readout 'best data we've ever seen' for a prostate cancer drug | #biotech #pharma #biotechsky #cancer #ProstateCancer
ESMO: J&J exec says RIPTAC readout is ‘best data we’ve ever seen’ for a prostate cancer drug
A year after paying over $3 billion for Halda Therapeutics, Johnson & Johnson has unveiled the first data from its shiny new RIPTAC pipeline that it believes could sustain its leading role in p | A ye...
www.fiercebiotech.com
October 26, 2026 at 2:37 PM
markfortner.bsky.social
Biotech stocks are surging. How investors can play the new drug innovation boom www.cnbc.com/2026/10/24/b...

#biotechsky #biotech
Biotech stocks are surging. How investors can play the new drug innovation boom
Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.
www.cnbc.com
October 25, 2026 at 3:06 PM
markfortner.bsky.social
Roche pays Zymeworks $55M for trispecific challenger to Amgen’s Imdelltra www.fiercebiotech.com/biotech/roch...

#biotechsky #biotech #pharma
Roche pays Zymeworks $55M for trispecific challenger to Amgen’s Imdelltra
Roche is paying Zymeworks $55 million upfront for ZW209,
www.fiercebiotech.com
October 24, 2026 at 2:38 PM
markfortner.bsky.social
Star adds $200M after spinout successes www.biopharmadive.com/news/star-th...

#biotechsky #biotech
Star adds $200M after spinout successes
Following exits for its subsidiaries Electra Therapeutics and Vega Therapeutics, Star is now mining for a new drug prospect.
www.biopharmadive.com
October 24, 2026 at 2:43 PM
markfortner.bsky.social
California startup says it injected AI-designed virus into humans for first time | #biotech #biotechsky #AI
California startup says it has injected AI-designed virus into humans for first time
Radical Numerics claims their AI-driven approach can lead to rapid, on-demand generation of phages
www.independent.co.uk
October 23, 2026 at 2:20 PM
markfortner.bsky.social
Protein degrader specialist Lycia prices $318M IPO www.biopharmadive.com/news/lycia-t...

#biotechsky #biotech #TPD
Protein degrader specialist Lycia prices $318M IPO
Funds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as well as the autoimmune disorder Graves’ disease.
www.biopharmadive.com
October 24, 2026 at 2:39 PM
markfortner.bsky.social
Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals

www.fiercebiotech.com/biotech/trea...

#biotechsky #biotech #pharma
Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals
The U.S. | Despite the sweeping scope of the ban covering various types of drug molecules, biopharma business development teams can breathe a measured sigh of relief.
www.fiercebiotech.com
October 24, 2026 at 3:18 PM
markfortner.bsky.social
GSK, Ionis win US approval for first-of-its-kind hepatitis B drug www.biopharmadive.com/news/gsk-ion...

#biotech #biotechsky #pharma
GSK, Ionis win US approval for first-of-its-kind hepatitis B drug
Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s goal of reaching £40 billion in annual revenue by 2031.
www.biopharmadive.com
October 24, 2026 at 2:40 PM
markfortner.bsky.social
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results www.biopharmadive.com/news/moderna...

#biotechsky #biotech #pharma
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reaction,...
www.biopharmadive.com
October 24, 2026 at 2:42 PM
markfortner.bsky.social
Tango combo clears Rasonque bar; Takeda's Innocent bet gets early returns | #biotech #pharma #biotechsky #cancer
Tango combo clears Rasonque bar; Takeda's Innovent bet gets early returns
Tango’s vopimetostat-Rasonque combo posts 82% response rate in pancreatic cancer at ESMO; Takeda, Novartis and BMS also report data.
endpoints.news
October 23, 2026 at 2:50 PM
markfortner.bsky.social
‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data www.fiercebiotech.com/biotech/it-w...

#biotech #cancer #biotechsky #pharma
‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
Merck & Co. and Moderna always knew they would be making headlines in Madrid this week—just not in the way it panned out. | Merck & Co. and Moderna always knew they would be making headlines in Madrid...
www.fiercebiotech.com
October 24, 2026 at 2:36 PM
markfortner.bsky.social
Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer | #cancer #PancreaticCancer #biotech #biotechsky
Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer
An experimental drug combination led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, Tango Therapeutics reported.
www.statnews.com
October 23, 2026 at 8:54 PM
markfortner.bsky.social
A German biotech has big ambitions in cancer. Now it needs to get a medicine approved | #biotech #biotechsky #cancer
A German biotech has big ambitions in cancer. Now it needs to get a medicine approved
After a quarter century of work, the German biotech Immatics is facing a pivotal moment as it awaits Phase 3 results for its lead candidate in melanoma.
www.statnews.com
October 21, 2026 at 6:27 PM
markfortner.bsky.social
AbbVie's next-gen Crohn's disease combo beats Skyrizi in phase 2 trial | #biotech #biotechsky
AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial
AbbVie’s next-generation Crohn’s disease combination candidate has
www.fiercebiotech.com
October 20, 2026 at 7:21 PM
markfortner.bsky.social
Roche returns to China’s ADC powerhouse Hansoh for $15B biobucks pact | #biotech #biotechsky #pharma www.fiercebiotech.com/biotech/roch...
Roche returns to China’s ADC powerhouse Hansoh for $15B biobucks pact
A year after their first antibody-drug conjugate (ADC) team-up, Roche has returned to Hansoh Pharmaceutical for a mammoth $15 billion b | A year after their first antibody-drug conjugate team-up, Roche has returned to Hansoh Pharmaceutical for a mammoth $15 billion biobucks pact.
www.fiercebiotech.com
October 20, 2026 at 7:48 PM
markfortner.bsky.social
Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win | #biotech #pharma #biotechsky
Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win
Germany’s Merck KGaA has picked up S | Germany’s Merck KGaA has picked up Silence Therapeutics to the tune of $1.3 billion in the wake of the British biotech’s mid-stage success for its challenger to ...
www.fiercebiotech.com
October 20, 2026 at 1:59 PM